

ORIGINAL

TSCA NON-CONFIDENTIAL BUSINESS INFORMATION

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8EHQ-12- 18575	89120000307	3 30 12

COMMENTS: 8EFU

DOES NOT CONTAIN CBI

M, R # 343137



8EHQ-0312-18575B
89120000307

DuPont Haskell Global Centers
for Health and Environmental Sciences
1090 Elkton Road, P.O. Box 50
Newark, DE 19714-0050

RECEIVED
OPPT CBIC

2012 MAR 30 AM 11:04

March 29, 2012

Via Federal Express

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
1201 Constitution Ave., NW
Washington, DC 20004



Dear 8(e) Coordinator:

8EHQ-12-18575
2-Pyridinesulfonamide, 3-(ethylsulfonyl)-
CAS#: 117671-01-9

This letter is to inform you of the results of a repeat dose oral toxicity study with the above referenced test substance.

The test substance was given to SD rats daily gavage (5/sex/group) for 4 consecutive weeks at dose levels of 0, 50, 150, 450, 1000 mg/kg/day (control, low, intermediate I, intermediate II and high, respectively). Daily and weekly clinical examinations were performed. Body weight, food consumption, and water consumption were measured weekly. Ophthalmological examination was performed pretest (all animals) and at week 4 (control group and high dose animals). Clinical pathology and anatomic pathology investigations were performed after 4 weeks of exposure.

No mortality occurred during the study. Polyuria was noted from day 15 in intermediate I males and in both sexes from the intermediate II and high dose groups. A convulsive episode (pedalling behaviour for about 10 seconds) was noted in one high dose female on day 23. Thin appearance and piloerection were noted in one high dose male on day 26. There were statistically significant, dose-related reductions in body weight gains in intermediate I dose males and in intermediate II and high dose males and females. A reduction in food consumption was noted for high dose males and females. A significant increase in water consumption was noted for intermediate I dose males and for intermediate II and high dose males and females. Bilirubin was slightly, but statistically significantly higher in high dose males and females and in intermediate II males when compared to control. There were no other test substance-related changes in clinical pathology parameters. Following statistically significant changes in organ weights were noted: a) lower absolute adrenal weights for high dose females, b) higher relative adrenal weights for intermediate II and high dose males, c) lower absolute testes weights for high dose males, d) higher absolute kidney weights were higher for high dose females and relative to body weight values for intermediate I, intermediate II and high dose males and females, and e) higher absolute liver weights for intermediate II and high dose females and for all doses males and relative to body weight values for intermediate I, intermediate II and high dose females. Pale areas in the gastric mucosa of all high dose males and females, 2 intermediate II males, 3 intermediate II females, and 2 intermediate I males and small testes in 2 high dose males were noted during gross observations. Acanthosis with hyperkeratosis in fore stomach was observed with a dose-related frequency in intermediate I males and in both sexes in intermediate II and high dose groups. Two high dose males showed atrophy/degeneration of the seminiferous tubules with presence of multinucleated giant cells in the lumina of tubules. Absence of sperm was noted in the epididymis of one of the males.



CONTAINS NO CBI

This information is submitted in accordance with current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act or, where it is not clear that reporting criteria have been met, it is submitted as a precautionary measure and because it is information in which EPA may have an interest.

Sincerely,

A handwritten signature in black ink, appearing to read 'S. Satheesh Anand', with a long horizontal flourish extending to the right.

S. Satheesh Anand, Ph.D., DABT
Senior Research Toxicologist

SSA/FOO: jhh
(302) 366-5314

FedEx® US Airbill

Express

8753 8029 2399

1 From This portion can be removed for Recipient's records.

Date 2/1/95 FedEx Tracking Number 875380292399

Sender's Name _____ Phone _____

Company _____

Address _____ Dept./Room/Suite/Room _____

City _____ State _____ ZIP _____

2 Your Internal Billing Reference _____


3 To Recipient's Name _____ Phone _____

Company _____

Address _____
We cannot deliver to P.O. boxes or P.O. ZIP codes.

Address _____
Use this line for the HOLD location address or for continuation of your shipping address.

City _____ State _____ ZIP _____



8753 8029 2399



tedex.com 1.800.GoFedEx 1.800.463.3339

4a Express Package Service * To most locations.

FedEx Priority Overnight Next business morning - Friday shipments will be delivered on Monday unless SATURDAY Delivery is selected.

FedEx 2Day Second business day** - Thursday shipments will be delivered on Monday unless SATURDAY Delivery is selected.

4b Express Freight Service ** To most locations.

FedEx 1Day Freight Next business day** - Friday shipments will be delivered on Monday unless SATURDAY Delivery is selected.

FedEx 2Day Freight Second business day** - Thursday shipments will be delivered on Monday unless SATURDAY Delivery is selected.

5 Packaging *Declared value limit \$500.
 FedEx Envelope*
 FedEx Pak* (includes FedEx Small Pak and FedEx Large Pak)
 FedEx Box
 FedEx Tube
 Other

6 Special Handling and Delivery Signature Options

SATURDAY Delivery
 NOT available for FedEx Standard Overnight, FedEx Express Saver, or FedEx 3Day Freight.

No Signature Required Package may be left without obtaining a signature for delivery.

Direct Signature Someone at recipient's address may sign for delivery. **Fee applies.**

Indirect Signature If no one is available at recipient's address, someone at a neighboring address may sign for delivery. **Fee applies.** residential deliveries only.

Does this shipment contain dangerous goods?
 No One box must be checked.
 Yes As per attached Shipper's Declaration. Not required.
 Yes Shipper's Declaration required. Not permitted to be shipped in FedEx packaging or placed in a FedEx Express Drop Box.

7 Payment Bill to:
 Sender I will be billed.
 Recipient
 Third Party
 Credit Card
 Cash/Check

Total Packages _____ Total Weight _____ lbs.

Your liability is limited to \$100 unless you declare a higher value. See the current FedEx Service Guide for details.

Rev. Date 2/10 • Part #196279 • ©1994-2010 FedEx • PRINTED IN U.S.A. SIS

609